Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Key points in second-line therapy for chronic myeloid leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2026

Ono Takaaki

Abstract excerpt

Tyrosine kinase inhibitors (TKIs) have markedly improved the prognosis of chronic myeloid leukemia (CML). In Japan, in addition to the four established first-line TKIs, asciminib is now approved as an initial therapy, expanding the treatment options. Nevertheless, more than 10% of patients treated with asciminib over 48 weeks, and approximately 20-30% of those receiving other TKIs over five years, require...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Niacinamide

Share to Pyrazoles

Share to Pyridazines

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 41780959
DOI: 10.11406/rinketsu.67.142

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Key points in second-line therapy for chronic myeloid leukemia].PMID 41780959Read ↗

[Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review].Semantic proximity Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.Semantic proximity Read ↗

Asciminib in chronic myeloid leukemia.Semantic proximity Read ↗

Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review.Semantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABLT315I Mutation--Review].Semantic proximity Read ↗

A review of the European LeukemiaNet recommendations for the management of CML.Semantic proximity Read ↗

Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaSemantic proximity Read ↗

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Semantic proximity Read ↗

Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.